Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy.

Abstract

INTRODUCTION:

For many cancers, tumour hypoxia is an adverse prognostic factor, and increases chemoradiation resistance; its importance in non-small cell lung cancer (NSCLC) is unproven. This study evaluated tumoural hypoxia using fluoroazomycin arabinoside ((18) F-FAZA) positron emission tomography (PET) scans among patients with locoregionally advanced NSCLC treated with definitive chemoradiation.

METHODS:

Patients with stage IIIA-IIIB NSCLC underwent (18) F-FAZA PET scans and (18) F-2-deoxyglucose (FDG)-PET scans within 4 weeks of commencing and 8 weeks following conventionally-fractionated concurrent platinum-based chemoradiation (60 Gy). Intra-lesional hypoxic volumes of the primary and nodal masses were compared with FDG-PET metabolic volumes. Baseline tumoural hypoxia was correlated with disease free survival (DFS).

RESULTS:

Seventeen patients underwent pre-treatment (18) F-FAZA PET and FDG-PET scans. Intra-lesional hypoxia was identified on 11 scans (65%). Baseline lesional hypoxic volumes were consistently smaller than FDG-PET volumes (P = 0.012). There was no statistical difference between the mean FDG-PET volumes in patients with or without baseline hypoxia (P = 0.38). Eight patients with baseline hypoxia had post treatment (18) F-FAZA scans and 6 of these (75%) had resolution of imageable hypoxia following chemoradiation. The DFS was not significantly different between the hypoxic or non-hypoxic groups (median 0.8 years and 1.3 years respectively, P = 0.42).

CONCLUSIONS:

Intra-lesional hypoxia, as detected by (18) F-FAZA PET, was present in 65% of patients with locally-advanced NSCLC and resolved in the majority of patients following chemoradiation. Larger studies are required to evaluate the prognostic significance of the presence and resolution of hypoxia assessed by PET in NSCLC.

• Authors: Mateya E Trinkaus, Rob Blum, Danny Rischin, Jason Callahan, Mathias Bressel, Tatiana Segard, Peter Roselt, Peter Eu, David Binns, Michael P MacManus, David Ball, Rodney J Hicks
• Journal: Journal of medical imaging and radiation oncology (J Med Imaging Radiat Oncol) Vol. 57 Issue 4 Pg. 475-81 (Aug 2013) ISSN: 1754-9485 [Electronic] Australia
• PMID: 23870348 (Publication Type: Clinical Trial, Phase I, Journal Article)
• Copyright: © 2013 The Royal Australian and New Zealand College of Radiologists.

Chemical References

• Nitroimidazoles
• Radiopharmaceuticals
• fluoroazomycin arabinoside

Topics

• Aged
• Aged, 80 and over
• Carcinoma, Non-Small-Cell Lung (diagnostic imaging, metabolism, therapy)
• Cell Hypoxia
• Chemoradiotherapy (methods)
• Female
• Humans
• Lung Neoplasms (diagnostic imaging, metabolism, therapy)
• Male
• Middle Aged
• Nitroimidazoles (pharmacokinetics)
• Positron-Emission Tomography (methods)
• Radiopharmaceuticals (pharmacokinetics)
• Reproducibility of Results
• Sensitivity and Specificity
• Treatment Outcome